<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Saturday June 1, 2019</th>
<th>Time/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sarcoma</strong>&lt;br&gt;COG/NRG Oncology collaboration</td>
<td>Results of the dose-finding phase of ARST 1321 from the Children’s Oncology Group and NRG Oncology: Neoadjuvant chemoradiation or radiation therapy +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcomas&lt;br&gt;Presenter: Yen-Lin Chen&lt;br&gt;Abstract #: 11070  (Poster Session)</td>
<td>8:00 am - 11:00 am&lt;br&gt;Sarcoma&lt;br&gt;<strong>Poster Board:</strong> #393&lt;br&gt;<strong>Location:</strong> South Bldg, L3, Hall A</td>
</tr>
<tr>
<td><strong>Sarcoma</strong>&lt;br&gt;NRG-DT001</td>
<td>MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma with wild-type TP53: A phase IB study (NRG-DT001)&lt;br&gt;Presenter: Meng Xu Welliver&lt;br&gt;Abstract #: TPS11076  Trials in Progress (Poster Session)</td>
<td>8:00 am - 11:00 am&lt;br&gt;Sarcoma&lt;br&gt;<strong>Poster Board:</strong> #398a&lt;br&gt;<strong>Location:</strong> South Bldg, L3, Hall A</td>
</tr>
<tr>
<td><strong>Lung</strong>&lt;br&gt;NRG-LU001 Best of ASCO</td>
<td>Initial reporting of NRG-LU001, randomized phase II trial of concurrent chemoradiotherapy +/- metformin in locally advanced non-small cell lung cancer&lt;br&gt;Presenter: Theodoros Tsakiridis&lt;br&gt;Abstract #: 8502  (Oral Abstract Session)  CE: 3</td>
<td>1:15 pm - 4:15 pm&lt;br&gt;Lung—Non-Small Cell&lt;br&gt;Local-Regional/Small Cell/Other Thoracic Cancers 1:39 pm - 1:51 pm&lt;br&gt;<strong>Location:</strong> Lakeside, L3, Hall D2</td>
</tr>
<tr>
<td><strong>Ovarian</strong>&lt;br&gt;GOG 9923</td>
<td>A phase I study of veliparib incorporated into front-line platinum based chemotherapy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/NRG trial&lt;br&gt;Presenter: Deborah Kay Armstrong&lt;br&gt;Abstract #: 5523  (Poster Discussion Session)  CE: 1.5</td>
<td>1:15 pm - 4:15 pm&lt;br&gt;Gynecologic Cancer&lt;br&gt;<strong>Poster Board:</strong> #346&lt;br&gt;<strong>Location:</strong> South Bldg, L3, Hall A&lt;br&gt;<strong>Discussion:</strong> 4:30 pm - 6:00 pm&lt;br&gt;5:36 pm - 5:48 pm&lt;br&gt;<strong>Location:</strong> South Bldg, L4, S406</td>
</tr>
<tr>
<td><strong>Endometrial</strong>&lt;br&gt;NRG-GY012</td>
<td>NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer&lt;br&gt;Presenter: Helen Mackay&lt;br&gt;Abstract #: TPS5609  Trials in Progress (Poster Session)</td>
<td>1:15 pm - 4:15 pm&lt;br&gt;Gynecologic Cancer&lt;br&gt;<strong>Poster Board:</strong> #424b&lt;br&gt;<strong>Location:</strong> South Bldg, L3, Hall A</td>
</tr>
<tr>
<td><strong>Head &amp; Neck</strong>&lt;br&gt;NRG-HN003</td>
<td>NRG-HN003: Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy, and MK-3475 (Pembrolizumab) in high risk head and neck squamous cell carcinoma&lt;br&gt;Presenter: Julie E. Bauman&lt;br&gt;Abstract #: 6023  (Poster Discussion Session)  CE: 1.5</td>
<td>1:15 pm - 4:15 pm&lt;br&gt;Head and Neck&lt;br&gt;<strong>Poster Board:</strong> #12&lt;br&gt;<strong>Location:</strong> South Bldg, L3, Hall A&lt;br&gt;<strong>Discussion:</strong> 4:30 pm - 6:00 pm&lt;br&gt;5:36 pm - 5:48 pm&lt;br&gt;<strong>Location:</strong> South Bldg, L1, S100a</td>
</tr>
<tr>
<td><strong>Head &amp; Neck</strong>&lt;br&gt;NRG-HN004</td>
<td>Safety of radiotherapy with concurrent and adjuvant MEDI4736 (durvalumab) in patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin: NRG-HN004&lt;br&gt;Presenter: Loren K. Mell&lt;br&gt;Abstract #: 6065  (Poster Session)</td>
<td>1:15 pm - 4:15 pm&lt;br&gt;Head and Neck&lt;br&gt;<strong>Poster Board:</strong> #54&lt;br&gt;<strong>Location:</strong> South Bldg, L3, Hall A</td>
</tr>
<tr>
<td><strong>Colorectal</strong>&lt;br&gt;SWOG1417CD/ NRG Oncology collaboration</td>
<td>Design and accrual of S1417CD: Development of a prospective financial impact assessment tool in patients with metastatic colorectal cancer&lt;br&gt;Presenter: Veena Shankaran&lt;br&gt;Abstract #: TPS6652  (Poster Session)</td>
<td>1:15 pm - 4:15 pm&lt;br&gt;Health Services Research, Clinical Informatics, and Quality of Care&lt;br&gt;<strong>Poster Board:</strong> #441b&lt;br&gt;<strong>Location:</strong> South Bldg, L3, Hall A</td>
</tr>
<tr>
<td><strong>Colon</strong>&lt;br&gt;NSABP C-05 through C-08 (ACCENT)</td>
<td>Re-evaluating disease-free survival as an endpoint versus overall survival in adjuvant colon cancer trials with chemotherapy +/- biologics: An updated surrogate analysis based on 18,886 patients from the ACCENT database&lt;br&gt;Presenter: Qian Shi&lt;br&gt;Abstract #: 3502  (Oral Abstract Session)  CE: 3</td>
<td>3:00 pm - 6:00 pm&lt;br&gt;Gastrointestinal (Colorectal)&lt;br&gt;Cancer 3:24 pm - 3:36 pm&lt;br&gt;<strong>Location:</strong> North Bldg, L3, Hall B1</td>
</tr>
<tr>
<td>Disease Site &amp; Study #</td>
<td>Sunday June 2, 2019</td>
<td>Time/Location</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Endometrial GOG-0210 GOG-8015</td>
<td>Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial</td>
<td>8:00 am - 9:30 am Clinical Science Symposium: Gynecologic Cancer Are We Hitting the Bull's-eye With Targeted Therapy? 8:00 am - 8:12 am Location: South Bldg, L4, S406</td>
</tr>
<tr>
<td>Head &amp; Neck RTOG 0234</td>
<td>Evolutionary action score of TP53 analysis in pathologically high-risk HPV-negative head and neck cancer from a phase II clinical trial: NRG Oncology RTOG 0234</td>
<td>8:00 am - 9:30 am Clinical Science Symposium: Head and Neck Cancer Dissecting Genomic Biomarkers in Head and Neck Cancer 8:24 am - 8:36 am Location: Lakeside, L4, E450</td>
</tr>
<tr>
<td>Brain NRG-CC001</td>
<td>NRG Oncology CC001: A phase III trial of hippocampal avoidance in addition to whole-brain radiotherapy plus memantine to preserve neurocognitive function in patients with brain metastases</td>
<td>8:00 am - 11:00 am Central Nervous System Tumors Poster Board: #198 Location: South Bldg, L3, Hall A Discussion: 4:30 pm - 6:00 pm 4:30 pm - 4:42 pm Location: South Bldg, L4, S404</td>
</tr>
<tr>
<td>Breast NSABP B-51/RTOG 1304</td>
<td>NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy post mastectomy or the addition of RNRT to whole breast RT post breast-conserving surgery reduces invasive breast cancer recurrence-free interval in patients with pathologically positive axillary nodes who are ypN0 after neoadjuvant chemotherapy</td>
<td>8:00 am - 11:00 am Breast Cancer - Local/Regional/Adjuvant Poster Board: #90a Location: South Bldg, L3, Hall A</td>
</tr>
<tr>
<td>Breast NRG-BR002</td>
<td>NRG-BR002: A phase II/III trial of standard of care therapy with or without stereotactic body radiotherapy and/or surgical ablation for newly oligometastatic breast cancer</td>
<td>8:00 am - 11:00 am Breast Cancer - Metastatic Poster Board: #189b Location: South Bldg, L3, Hall A</td>
</tr>
<tr>
<td>Lung NRG-CC003</td>
<td>NRG Oncology CC003: A randomized phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer</td>
<td>8:00 am - 11:00 am Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster Board: #329b Location: South Bldg, L3, Hall A</td>
</tr>
<tr>
<td>Disease Site &amp; Study #</td>
<td>Monday June 3, 2019</td>
<td>Time/Location</td>
</tr>
<tr>
<td>------------------------</td>
<td>--------------------</td>
<td>---------------</td>
</tr>
<tr>
<td><strong>Head &amp; Neck</strong></td>
<td><strong>Clinical Controversies: The Changing Landscape of Standard Therapy in Squamous Cell Carcinoma of the Head and Neck</strong>&lt;br&gt;<strong>RTOG 1016</strong>&lt;br&gt;<strong>Presenter:</strong> Andy Trotti&lt;br&gt;<strong>TICKETED SESSION</strong>&lt;br&gt;<strong>CE:</strong> 1.25</td>
<td><strong>9:45 am - 10.05 am</strong>&lt;br&gt;<strong>Location:</strong> Lakeside, L2, E253d</td>
</tr>
<tr>
<td><strong>Sarcoma</strong>&lt;br&gt;<strong>COG/NRG Oncology collaboration</strong></td>
<td>Preoperative chemoradiation +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcoma: A report from Children's Oncology Group and NRG Oncology&lt;br&gt;<strong>Presenter:</strong> Aaron R. Weiss&lt;br&gt;<strong>Abstract #:</strong> 11002  <strong>(Oral Abstract Session)</strong>&lt;br&gt;<strong>CE:</strong> 3</td>
<td><strong>8:00 am - 11:00 am</strong>&lt;br&gt;<strong>Sarcoma</strong>&lt;br&gt;<strong>8:24 pm - 8:36 pm</strong>&lt;br&gt;<strong>Location:</strong> Lakeside, L4, E450</td>
</tr>
<tr>
<td><strong>Breast</strong>&lt;br&gt;<strong>PACCT-1</strong>&lt;br&gt;<strong>ECOG-ACRIN/NRG Oncology collaboration</strong></td>
<td>Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer by age and the 21-gene recurrence score in TAILORx&lt;br&gt;<strong>Presenter:</strong> Joseph A. Sparano&lt;br&gt;<strong>Abstract #:</strong> 503  <strong>(Oral Abstract Session)</strong>&lt;br&gt;<strong>CE:</strong> 3</td>
<td><strong>9:45 am - 12:45 pm</strong>&lt;br&gt;<strong>Breast Cancer - Local/Regional/Adjuvant</strong>&lt;br&gt;<strong>10:45 am - 10:57 am</strong>&lt;br&gt;<strong>Location:</strong> Lakeside, L3, Hall D2</td>
</tr>
<tr>
<td><strong>Breast</strong>&lt;br&gt;<strong>NSABP B-39/ RTOG 0413</strong>&lt;br&gt;<strong>Best of ASCO</strong></td>
<td>Patient-reported outcomes in NRG oncology/NSABP B-39/ RTOG 0413: A randomized phase III study of conventional whole breast irradiation versus partial breast irradiation in stage 0, I, or II breast cancer&lt;br&gt;<strong>Presenter:</strong> Patricia A. Ganz&lt;br&gt;<strong>Abstract #:</strong> 508  <strong>(Oral Abstract Session)</strong>&lt;br&gt;<strong>CE:</strong> 3</td>
<td><strong>9:45 am - 12:45 pm</strong>&lt;br&gt;<strong>Breast Cancer - Local/Regional/Adjuvant</strong>&lt;br&gt;<strong>12:09 pm - 12:21 pm</strong>&lt;br&gt;<strong>Location:</strong> Lakeside, L3, Hall D2</td>
</tr>
<tr>
<td><strong>Colon</strong>&lt;br&gt;<strong>NSABP C-05 through C-08 (ACCENT)</strong></td>
<td>Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an ACCENT meta-analysis of seven studies&lt;br&gt;<strong>Presenter:</strong> Julien Taieb&lt;br&gt;<strong>Abstract #:</strong> 3525  <strong>(Poster Session)</strong></td>
<td><strong>8:00 am - 11:00 am</strong>&lt;br&gt;<strong>Gastrointestinal (Colorectal) Cancer</strong>&lt;br&gt;<strong>Poster Board:</strong> #17&lt;br&gt;<strong>Location:</strong> South Bldg, L3, Hall A</td>
</tr>
<tr>
<td><strong>Lung</strong>&lt;br&gt;<strong>ECOG-ACRIN 5508/NRG collaboration</strong></td>
<td>ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC&lt;br&gt;<strong>Presenter:</strong> Suresh S. Ramalingam&lt;br&gt;<strong>Abstract #:</strong> 9002  <strong>(Oral Abstract Session)</strong>&lt;br&gt;<strong>CE:</strong> 3</td>
<td><strong>8:00 am - 11:00 am</strong>&lt;br&gt;<strong>Lung Cancer—Non-Small Cell Metastatic</strong>&lt;br&gt;<strong>8:24 am - 8:36 am</strong>&lt;br&gt;<strong>Location:</strong> North Bldg, L3, Hall B1</td>
</tr>
<tr>
<td><strong>Uterus/Ovary</strong>&lt;br&gt;<strong>GOG-0261</strong></td>
<td>A randomized phase 3 trial of paclitaxel plus carboplatin versus paclitaxel plus ifosfamide in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial&lt;br&gt;<strong>Presenter:</strong> Matthew A. Powell&lt;br&gt;<strong>Abstract #:</strong> 5500  <strong>(Oral Abstract Session)</strong>&lt;br&gt;<strong>CE:</strong> 3</td>
<td><strong>1:15 pm - 4:15 pm</strong>&lt;br&gt;<strong>Gynecologic Cancer</strong>&lt;br&gt;<strong>1:15 pm - 1:27 pm</strong>&lt;br&gt;<strong>Location:</strong> South Bldg, L4, S406</td>
</tr>
<tr>
<td><strong>Brain</strong>&lt;br&gt;<strong>RTOG 9802</strong>&lt;br&gt;<strong>Best of ASCO</strong></td>
<td>Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802&lt;br&gt;<strong>Presenter:</strong> Erica Hlavin Bell&lt;br&gt;<strong>Abstract #:</strong> 2002  <strong>(Oral Abstract Session)</strong>&lt;br&gt;<strong>CE:</strong> 3</td>
<td><strong>1:15 pm - 4:15 pm</strong>&lt;br&gt;<strong>Central Nervous System Tumors</strong>&lt;br&gt;<strong>2:03 pm - 2:15 pm</strong>&lt;br&gt;<strong>Location:</strong> South Bldg, L1, S102</td>
</tr>
<tr>
<td><strong>Genitourinary</strong>&lt;br&gt;<strong>ECOG-ACRIN 8143/ NRG - collaboration</strong></td>
<td>PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143)&lt;br&gt;<strong>Presenter:</strong> Lauren Christine Harshman&lt;br&gt;<strong>Abstract #:</strong> TPS4597  <strong>(Poster Session)</strong></td>
<td><strong>1:15 pm - 4:15 pm</strong>&lt;br&gt;<strong>Genitourinary (Nonprostate) Cancer</strong>&lt;br&gt;<strong>Poster Board:</strong> #417b&lt;br&gt;<strong>Location:</strong> South Bldg, L3, Hall A</td>
</tr>
<tr>
<td>Disease Site &amp; Study #</td>
<td>Saturday June 1, 2019</td>
<td>Time/Location</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------------</td>
<td>---------------</td>
</tr>
</tbody>
</table>
| **Head & Neck**  
RTOG 3504  
Foundation  
**Saturday June 1, 2019**  
**Time/Location**  
1:15 pm - 4:15 pm  
Head and Neck Cancer  
**Poster Board:** #62  
**Location:** South Bldg, L3, Hall A | Safety and disease control achieved with the addition of nivolumab to chemoradiotherapy for intermediate (IR) and high-risk locally-regionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504  
**Presenter:** Maura L. Gillison  
**Abstract #:** 6073 (Poster Session) | 1:15 pm - 4:15 pm  
Head and Neck Cancer  
**Poster Board:** #62  
**Location:** South Bldg, L3, Hall A |

<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Sunday June 2, 2019</th>
<th>Time/Location</th>
</tr>
</thead>
</table>
| **Breast**  
NSABP FB-11  
Foundation  
**Sunday June 2, 2019**  
**Time/Location**  
8:00 am - 11:00 am  
Breast Cancer - Local/Regional/Adjuvant  
**Poster Board:** #62  
**Location:** South Bldg, L3, Hall A | Biomarker analysis of PALLET a neoadjuvant trial of letrozole ± palbociclib  
**Presenter:** Mitchell Dowsett  
**Abstract #:** 570 (Poster Session) | 8:00 am - 11:00 am  
Breast Cancer - Local/Regional/Adjuvant  
**Poster Board:** #62  
**Location:** South Bldg, L3, Hall A |
| **Breast**  
NSABP B-56  
I  
Industry  
**Sunday June 2, 2019**  
**Time/Location**  
8:00 am - 11:00 am  
Breast Cancer - Local/Regional/Adjuvant  
**Poster Board:** #2  
**Location:** South Bldg, L3, Hall A  
**Discussion:** 4:30 pm - 4:42 pm  
**Location:** Lakeside, L3, Hall D2 | Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study  
**Presenter:** Otto Metzger Filho  
**Abstract #:** 510 (Poster Discussion Session)  
**CE:** 1.5 | 8:00 am - 11:00 am  
Breast Cancer - Local/Regional/Adjuvant  
**Poster Board:** #2  
**Location:** South Bldg, L3, Hall A  
**Discussion:** 4:30 pm - 4:42 pm  
**Location:** Lakeside, L3, Hall D2 |
| **Breast**  
NSABP B-41  
Foundation  
**Sunday June 2, 2019**  
**Time/Location**  
8:00 am - 11:00 am  
Breast Cancer - Local/Regional/Adjuvant  
**Poster Board:** #3  
**Location:** South Bldg, L3, Hall A  
**Discussion:** 4:30 pm - 6:00 pm  
**Location:** Lakeside, L3, Hall D2 | NSABP B-41, a randomized neoadjuvant trial: Genes and signatures associated with pathologic complete response  
**Presenter:** Sandra M. Swain  
**Abstract #:** 511 (Poster Discussion Session)  
**CE:** 1.5 | 8:00 am - 11:00 am  
Breast Cancer - Local/Regional/Adjuvant  
**Poster Board:** #3  
**Location:** South Bldg, L3, Hall A  
**Discussion:** 4:30 pm - 6:00 pm  
**Location:** Lakeside, L3, Hall D2 |
| **Breast**  
NSABP B-50  
I  
Foundation  
**Sunday June 3, 2019**  
**Time/Location**  
8:00 am - 11:00 am  
Breast Cancer - Local/Regional/Adjuvant  
**Poster Board:** #5  
**Location:** South Bldg, L3, Hall A  
**Discussion:** 4:30 pm - 6:00 pm  
**Location:** Lakeside, L3, Hall D2 | Patient-reported outcomes from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer  
**Presenter:** Andreas Schneeweiss  
**Abstract #:** 513 (Poster Discussion Session)  
**CE:** 1.5 | 8:00 am - 11:00 am  
Breast Cancer - Local/Regional/Adjuvant  
**Poster Board:** #5  
**Location:** South Bldg, L3, Hall A  
**Discussion:** 4:30 pm - 6:00 pm  
**Location:** Lakeside, L3, Hall D2 |
| **Breast**  
NSABP B-59/GBG 96-GeparDouze  
**Sunday June 3, 2019**  
**Time/Location**  
8:00 am - 11:00 am  
Breast Cancer - Local/Regional/Adjuvant  
**Poster Board:** #92b  
**Location:** South Bldg, L3, Hall A | NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer followed by adjuvant atezolizumab or placebo  
**Presenter:** Charles E. Geyer, Jr  
**Abstract #:** TPS605 Trials in Progress (Poster Session) | 8:00 am - 11:00 am  
Breast Cancer - Local/Regional/Adjuvant  
**Poster Board:** #92b  
**Location:** South Bldg, L3, Hall A |

<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Monday June 3, 2019</th>
<th>Time/Location</th>
</tr>
</thead>
</table>
| **Rectal**  
NSABP FR-2  
Foundation  
**Monday June 3, 2019**  
**Time/Location**  
8:00 am - 11:00 am  
Gastrointestinal (Colorectal) Cancer  
**Poster Board:** #109b  
**Location:** South Bldg, L3, Hall A | NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemotherapy (NAC) in stage II-IV rectal cancer  
**Presenter:** Thomas J. George  
**Abstract #:** TPS3620 Trials in Progress (Poster Session) | 8:00 am - 11:00 am  
Gastrointestinal (Colorectal) Cancer  
**Poster Board:** #109b  
**Location:** South Bldg, L3, Hall A |